查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832478

伴隨診斷市場（按產品類型、應用、最終用戶和分銷管道）—全球預測，2025-2032

Companion Diagnostics Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年伴隨診斷市場將成長至 169.1 億美元，複合年成長率為 11.06%。

主要市場統計數據
基準年2024年 73億美元
預計2025年 81億美元
預測年份：2032年 169.1億美元
複合年成長率（%） 11.06%

權威介紹伴隨診斷如何重新定義臨床路徑以及診斷、治療和醫療保健交付中的策略價值

伴隨診斷正在改變實驗室科學與臨床決策的交叉領域，使患者分層和標靶治療選擇更加精準。該領域已從最初僅支持單藥聯合治療的小眾領域發展成為現代精準醫療策略的重要組成部分，影響著監管審查路徑、臨床試驗設計和商業性價值提案。隨著生物標記和伴隨檢測在治療研發中日益佔據優先地位，診斷工具正從輔助產品轉變為影響治療流程和付款人互動的策略資產。

同時，技術進步和跨學科合作正在拓展伴隨診斷的應用範圍。分子譜分析、數位病理學和數據分析領域的創新產生了更豐富的診斷訊號，為治療方法選擇和長期疾病管理提供資訊。本簡介概述了影響伴隨診斷格局的因素，概述了臨床效用和商業性應用之間的相互關係，並提出了相關人員如何使其營運能力與不斷變化的臨床和監管要求相協調的期望。

分子技術進步、監管調整和綜合臨床工作流程如何重塑伴隨診斷和臨床應用

在技​​術、法規和臨床實踐融合的推動下，伴隨診斷領域正在經歷一場變革。定序技術和多重檢測的進步正在擴展診斷範圍，使臨床醫生能夠從單一分析物檢測轉向全面的分子分析，從而捕捉複雜的疾病生物學特徵。這種演變，加上現實世界證據和自適應臨床試驗框架的日益普及，正在縮短從生物標記發現到臨床應用的時間，並為迭代檢驗創造新的機會。

法律規範正在適應這些進步，強調分析的穩健性、臨床有效性和上市後證據的產生。付款人和醫療保健系統正在重新調整報銷模式，以體現診斷主導的治療價值，而開發商也面臨著證明成本效益和改善患者預後的壓力。同時，數位化整合和實驗室自動化正在縮短週轉時間，提高可重複性，增強臨床醫生的信心，並支援更廣泛的工作流程整合。這些轉變正在增強診斷在精準醫療中的作用，同時也為商業化策略、供應鏈規劃和相關人員的證據產生帶來了複雜性。

隨著診斷技術的成熟，診斷開發商、製藥贊助商和臨床實驗室之間的夥伴關係也變得更加策略化和複雜化。證據共同產生和共同開發契約使市場策略更加協調一致，而數據共用聯盟則加速了生物標記的檢驗。這些趨勢標誌著一個更整合的生態系統的出現，在這個生態系統中，診斷不僅可以為治療決策提供訊息，而且在臨床開發和上市規劃中發揮核心作用。

評估不斷變化的關稅政策對診斷供應鏈、籌資策略和實驗室營運彈性的系統性影響

近期政策週期中宣布或實施的貿易政策變化和關稅措施，為伴隨診斷供應鏈帶來了新的變量，影響了試劑採購、設備採購和國際實驗室夥伴關係。對檢測設備、昂貴的定序儀器和進口試劑徵收的關稅改變了供應商的選擇動態，並可能刺激在地採購策略。為此，許多相關人員已開始重新評估供應商關係，避免關鍵投入的雙重採購，並探索在地化生產方案，以減輕貿易相關成本波動的影響。

除了直接採購成本外，關稅還影響依賴進口設備的臨床檢測和診斷製造商的資本規劃。採購週期正在發生變化，買家為了避開關稅窗口而推遲或加快採購，而供應商則重新評估其管道策略以保持競爭力。此外，關稅引發的物流和海關處理變化可能會影響前置作業時間，進而影響庫存管理和對臨床合作夥伴的服務水準承諾。在這種情況下，擁有靈活供應結構和本地製造及分銷能力的公司更有能力在不犧牲服務品質的情況下維持業務。

相關人員應從系統視角審視關稅的影響，不僅要考慮成本壓力，還要考慮貿易流變化所帶來的營運摩擦。戰略應對措施包括與供應商重新協商長期契約，以應對意外關稅；在監管途徑允許的情況下投資本地組裝和試劑混合；以及加強情景規劃以預測未來的貿易變化。這些措施將有助於在外部政策波動的情況下保持檢測服務的連續性，並支持穩健的商業化路徑。

細分市場主導的洞察，將檢測方式、臨床應用、用戶需求和分銷管道結合起來，為產品開發和商業化策略提供訊息

有效的細分分析能夠揭示技術優勢及其與臨床需求和機會的交集。從檢測方式的角度來看，免疫組織化學技術能夠提供成熟的組織生物標記讀數，並且仍然是許多病理學工作流程中不可或缺的一部分。次世代定序拓展了診斷的廣度和深度，並進一步細分為標靶定序（專注於與可操作變異比對的特定基因組合）；轉錄組定序（捕獲與機制闡明和抗藥性監測相關的基因表現表現譜）；以及全基因組定序（為複雜病例提供全面的基因組圖譜）。聚合酶鍊式反應因其速度和靈敏度而持續受到關注，並有專門的形式，例如用於絕對定量的數位PCR和用於高通量相對定量的定量PCR。

以應用為中心的細分揭示了測試在哪些領域推動臨床決策，以及開發資源應集中在何處。遺傳性疾病提供了早期檢測和家庭風險評估的機會；感染疾病需要快速靈敏的病原體鑑定和抗藥性分析平台；腫瘤學透過精準標靶治療，繼續成為伴隨診斷的主要臨床驅動力；藥物藥物基因體學則支持跨治療領域更安全、更有效的藥物選擇。每種應用都有不同的分析要求和檢驗範式，影響技術選擇和臨床實施策略。

終端用戶細分決定了銷售模式和服務交付預期。學術和研究機構通常優先考慮發現和轉化工作的靈活性和分析深度，而診斷實驗室則強調通量、合規性和可重複性。醫院將檢測整合到臨床工作流程中，並優先考慮週轉時間和臨床報告，而製藥公司則優先考慮與伴隨診斷和治療產品線以及臨床試驗整合的銜接。市場區隔進一步影響市場進入，直接競標安排支援臨床現場採購，經銷商銷售促進更廣泛的地理覆蓋，線上銷售支援在分散式檢測環境中快速訂購套件和耗材。這些細分提供了產品市場契合度的多層次視角，並指南了在開發、商業化和客戶支援方面投資的優先順序。

醫療保健基礎設施、監管方法和戰略夥伴關係將如何推動美洲、中東和北非以及亞太地區的差異化採用模式？

伴隨診斷的區域動態受不同的醫療基礎設施、監管方式和投資生態系統的影響。在美洲，整合的醫療服務提供者、強大的臨床試驗網路以及龐大的生物技術部門促進了新型診斷方法的早期應用，並促進了臨床醫生與產業之間的密切合作。這種環境支持將研究與臨床路徑連接起來的迭代檢驗和臨床效用研究，而報銷談判也越來越強調已證實的價值和療效的一致性。

歐洲、中東和非洲地區的應用曲線各不相同，這主要受監管環境和支付方趨勢的影響。歐洲部分地區擁有強大的學術中心和集中式公共衛生系統，能夠促進多中心合作和標準化工作，而中東和北非市場則更注重能力建設、實驗室基礎設施現代化和區域協調。跨境夥伴關係和診斷中心在將先進檢測能力擴展到這些地區更廣泛的患者群體方面發揮關鍵作用。

亞太地區以其實驗室基礎設施的快速投資、國內診斷製造業的成長以及龐大的患者群體而著稱，這些因素有助於轉化研究和真實世界證據的產生。政府主導的精準醫療計畫擴展計畫以及大型臨床中心的存在為擴展診斷服務創造了機會。相關人員必須應對不同地區的監管時間表、報銷框架和基礎設施限制，根據當地實際情況客製化市場准入和夥伴關係策略，同時利用全球證據產生來支持更廣泛的應用。

深入了解競爭定位、夥伴關係和能力堆棧，這些將決定診斷開發人員、實驗室和全方位服務供應商的成功

伴隨診斷領域的競爭由專業的檢測試劑開發商、儀器製造商、臨床實驗室網路以及綜合診斷和治療夥伴關係共同推動。在分析化學、分子生物學和病理學領域擁有深厚專業知識的公司利用專有平台和檢驗的工作流程來建立臨床可靠性。同時，擁有可擴展生產、監管經驗和協作開發模式的公司展現出加速伴隨檢測試劑臨床應用和市場開發的能力。

診斷開發商與藥品贊助商之間的策略聯盟仍然是共同開發與治療方法密切相關的檢測方法的重要途徑。此類夥伴關係通常延伸至證據產生、編碼和報銷策略以及上市後監管。此外，提供端到端檢測能力（包括集中式和分散式服務模式）的實驗室服務供應商在創新與臨床可及性之間的橋樑中發揮關鍵作用。投資於穩健品質系統、與電子健康記錄的互通性以及面向臨床醫生的報告工具​​的公司往往能夠實現更高的採用率並更好地融入到醫療護理途徑中。

新的競爭壓力將來自那些將診斷技術與先進的分析和決策支援解決方案相結合，從而對生物標記數據進行更具可操作性的縱向解讀的公司。這些混合產品標誌著市場轉向將分析績效與臨床效用和工作流程效率相結合的價值提案，從而為那些能夠在患者管理和醫療系統結果方面取得切實改善的機構帶來回報。

診斷開發人員和健康系統需要採取切實可行的策略措施，協調創新、供應鏈彈性和證據共同生成

為了有效應對不斷變化的診斷領域，產業領導者應優先考慮以下幾項策略要務。首先，開發能夠證明臨床實用性和操作可行性的產品，具體方法是將最終用戶需求納入檢測設計，在代表性效用中檢驗效能，並確保與臨床決策流程整合。這種協調可以減少實施過程中的摩擦，並支持與付款方就改善結果而非分析創新進行討論。

其次，透過多元化供應商、盡可能考慮本地製造和組裝，以及將關稅和物流方案納入採購計劃，以增強供應鏈的韌性。積極主動的供應商夥伴關係以及包含應急條款的長期契約，可以降低貿易和分銷中斷的風險，並支持實驗室的可靠運作。

第三，與藥品申辦方、臨床網路和衛生系統建立策略合作，共同產生證據，加速臨床整合。此類合作應建構風險共用機制，並圍繞可證實的患者獲益調整獎勵。對數據基礎設施和分析能力的投資將有助於產生更具說服力的真實世界證據，並持續監測其績效。

最後，投資於能夠反映最終用戶實際情況的商業化模式。這包括混合分銷模式，將與醫療服務提供者的直接接觸、與分銷商的合作以及耗材的數位管道相結合。將產品創新與臨床醫生教育、付款人參與計畫和精簡的監管策略相結合，可以提高產品成功推廣和持續臨床使用的可能性。

透明的混合方法研究框架，結合專家訪談、監管文件分析和案例研究綜合​​，以產生可操作的診斷見解

本研究採用定性和定量相結合的方法，以全面了解伴隨診斷領域的現狀。主要內容包括與臨床意見領袖、實驗室主任、監管專家和商業性相關人員的訪談，以了解營運挑戰、應用促進因素以及未滿足的臨床需求。這些訪談為評估分析平台、檢測效能特徵以及實際臨床工作流程中的整合障礙提供了一個框架。

二次研究包括廣泛檢索同儕審查文獻、監管指導文件、臨床實踐指南和公共聲明，以便在當前的科學和監管環境下進行分析。本研究對成功的診斷和治療聯合開發案例進行了比較分析，以識別證據生成、監管策略和市場進入計劃方面的最佳實踐和通用陷阱。

我們對主要和次要研究結果進行了三角綜合，以得出基於情境的供應鏈設計、商業化路徑和區域參與策略的啟示。與行業相關人員舉行了檢驗研討會，以完善結論並確保其實踐相關性。這種混合方法設計強調假設的透明度、洞察對輸入來源的可追溯性，以及根據組織決策需求量身定做的可操作建議。

簡明結論綜合了技術、監管和商業性要求，以指導伴隨診斷​​的策略投資和臨床整合

摘要：伴隨診斷正在重塑臨床路徑、臨床試驗設計和商業模式，在精準醫療中日益重要。定序和多重檢測技術的進步，加上監管和報銷機制的持續演進，正在提升人們對臨床效用和營運準備度的期望。供應鏈和貿易政策的動態變化增加了複雜性，使得韌性和策略採購成為商業化計畫的關鍵要素。

按產品類型、應用程式、最終用戶和分銷管道進行細分，有助於明確開發和上市要求，而區域動態則需要製定獨特的策略，以反映基礎設施、法規和付款方的差異。那些將卓越的分析能力與強大的證據生成、策略夥伴關係以及與臨床醫生一致的彙報和工作流程整合相結合的組織將獲得競爭優勢。總而言之，這些見解為尋求優先考慮伴隨診斷投資並推動臨床整合的領導者提供了清晰的基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將多組體學物標記整合到伴隨診斷檢測中以實現個人化治療
  • 擴展基於液態生物檢體的伴隨診斷，用於即時治療監測
  • 採用數位病理學和人工智慧演算法解釋伴隨診斷結果
  • 製藥公司和診斷開發公司合作共同開發標靶治療
  • 新興市場中成本效益高的POC伴隨診斷平台的出現
  • 監管協調舉措將簡化重點地區的伴隨診斷核准
  • 開發能夠同時分析多種生物標記的多重伴隨診斷
  • 增加對次世代定序面板的投資，用於全面的伴隨診斷測試

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章伴隨診斷市場（依產品類型）

  • 免疫組織化學
  • 原位雜合技術
  • 次世代定序
    • 標靶定序
    • 轉錄組定序
    • 全基因組序列分析
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 定量PCR

第9章伴隨診斷市場（按應用）

  • 遺傳性疾病
  • 感染疾病
  • 腫瘤學
  • 藥物基因組學

第 10 章 伴隨診斷市場（依最終使用者）

  • 學術研究機構
  • 診斷實驗室
  • 醫院
  • 製藥公司

第 11 章伴隨診斷市場（依通路）

  • 直接競標
  • 經銷商銷售
  • 網上銷售

第12章 伴隨診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 伴隨診斷市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 伴隨診斷市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Abbott Laboratories
    • Illumina, Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Agilent Technologies, Inc.
    • Siemens Healthineers AG
Product Code: MRR-433AB1DC2871

The Companion Diagnostics Market is projected to grow by USD 16.91 billion at a CAGR of 11.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.30 billion
Estimated Year [2025] USD 8.10 billion
Forecast Year [2032] USD 16.91 billion
CAGR (%) 11.06%

An authoritative introduction to how companion diagnostics are redefining clinical pathways and strategic value across diagnostics, therapeutics, and healthcare delivery

Companion diagnostics are changing the interface between laboratory science and clinical decision-making, enabling more precise patient stratification and targeted therapy selection. The field has matured from a niche enabler of single-drug pairings to an integral component of modern precision medicine strategies, influencing regulatory review pathways, clinical trial designs, and commercial value propositions. As therapeutic development increasingly prioritizes biomarkers and companion tests, diagnostic tools have transitioned from adjunctive products to strategic assets that shape treatment algorithms and payer conversations.

In parallel, technological advances and cross-disciplinary collaborations have broadened the applications of companion diagnostics. Innovations in molecular profiling, digital pathology, and data analytics have created richer diagnostic signals that inform both therapeutic selection and longitudinal disease management. This introduction outlines the drivers shaping the companion diagnostics environment, frames the interplay between clinical utility and commercial adoption, and sets expectations for how stakeholders can align operational capabilities with evolving clinical and regulatory demands.

How converging advances in molecular technology, regulatory adaptation, and integrated clinical workflows are reshaping companion diagnostics and clinical adoption

The companion diagnostics landscape is undergoing transformative shifts driven by converging forces in technology, regulation, and clinical practice. Advances in sequencing technologies and multiplexed assays have expanded the diagnostic repertoire, enabling clinicians to move beyond single-analyte tests toward comprehensive molecular profiling that captures complex disease biology. This evolution is paired with increasing acceptance of real-world evidence and adaptive clinical trial frameworks, which together compress the timeline from biomarker discovery to clinical adoption and create new opportunities for iterative validation.

Regulatory frameworks are adapting to these advances, with agencies emphasizing analytical robustness, clinical relevance, and post-market evidence generation. Payers and health systems are recalibrating reimbursement models to consider diagnostic-driven therapeutic value, prompting developers to demonstrate cost-effectiveness and patient outcome improvements. At the same time, digital integration and laboratory automation are reducing turnaround times and improving reproducibility, which enhances clinician confidence and supports broader workflow integration. These shifts collectively elevate the role of diagnostics in precision medicine while also introducing complexity in commercialization strategies, supply chain planning, and cross-stakeholder evidence generation.

As diagnostics mature, partnerships between diagnostic developers, pharmaceutical sponsors, and clinical laboratories are becoming more strategic and sophisticated. Collaborative evidence generation and co-development agreements are enabling more aligned go-to-market strategies, while data-sharing consortia are accelerating biomarker validation. These trends signal a more integrated ecosystem in which diagnostics not only inform therapeutic decisions but also play a central role in clinical development and market access planning.

Assessing the systemic consequences of evolving tariff policies on diagnostics supply chains, procurement strategies, and laboratory operational resilience

Trade policy shifts and tariff measures announced or implemented in recent policy cycles have introduced new variables into the supply chains that underpin companion diagnostics, with implications for reagent procurement, instrument sourcing, and international laboratory partnerships. Tariffs on laboratory equipment, high-value sequencing instruments, and imported reagents can alter supplier selection dynamics and motivate localized sourcing strategies. In response, many stakeholders have started reassessing vendor relationships, dual-sourcing critical inputs, and exploring regionalized manufacturing options to mitigate exposure to trade-related cost volatility.

Beyond direct procurement costs, tariffs influence capital planning for clinical laboratories and diagnostic manufacturers that rely on imported instrumentation. Procurement cycles are adapting as buyers delay or accelerate purchases to navigate tariff windows, and vendors are revising channel strategies to preserve competitiveness. Moreover, tariff-driven changes in logistics and customs processing can affect lead times, which in turn influence inventory management and service level commitments to clinical partners. In this context, firms with flexible supply arrangements and in-region manufacturing or distribution capabilities are better positioned to sustain operations without sacrificing service quality.

Stakeholders should view tariff impacts through a systems lens, considering not only incremental cost pressures but also the operational friction that arises from altered trade flows. Strategic responses include renegotiating long-term supplier contracts with tariff contingencies, investing in local assembly or reagent blending where regulatory pathways permit, and enhancing scenario planning to anticipate future trade shifts. These measures help maintain continuity of testing services and support resilient commercialization pathways despite external policy fluctuations.

Segment-driven insights that align assay modality, clinical application, user needs, and distribution channels to inform product development and commercialization strategies

Effective segmentation analysis illuminates where technical strengths intersect with clinical demand and commercial opportunity. When products are viewed through the lens of assay modality, Immunohistochemistry offers established tissue-based biomarker readouts that remain essential for many pathology workflows, while In Situ Hybridization complements tissue analysis with nucleic acid localization. Next Generation Sequencing expands diagnostic breadth and depth and is further differentiated by Targeted Sequencing, which focuses on specific gene panels aligned to actionable variants; Transcriptome Sequencing, which captures gene expression profiles relevant to mechanism elucidation and resistance monitoring; and Whole Genome Sequencing, which provides comprehensive genomic context for complex cases. Polymerase Chain Reaction retains prominence for its speed and sensitivity and includes specialized forms such as Digital PCR for absolute quantitation and Quantitative PCR for high-throughput relative quantitation.

Application-focused segmentation reveals where testing drives clinical decision-making and where development resources should be concentrated. Genetic Disorders present opportunities for early detection and family risk assessment, Infectious Diseases require rapid, sensitive platforms for pathogen identification and resistance profiling, Oncology continues to be the dominant clinical driver for companion diagnostics through precise targeting of therapies, and Pharmacogenomics supports safer and more effective medication selection across therapeutic areas. Each application imposes distinct analytical requirements and validation paradigms, influencing both technology choice and clinical implementation strategies.

End-user segmentation shapes distribution models and service delivery expectations. Academic and research institutes often prioritize flexibility and depth of analysis for discovery and translational work, while diagnostic laboratories emphasize throughput, regulatory compliance, and reproducibility. Hospitals integrate testing into clinical workflows and prioritize turnaround time and clinical reporting, whereas pharmaceutical companies focus on companion diagnostic alignment with therapeutic pipelines and clinical trial integration. Distribution channel segmentation further affects market access, with direct tender arrangements supporting institutional procurement, distributor sales facilitating broader geographic reach, and online sales enabling rapid ordering of kits and consumables for decentralized testing environments. Together, these segmentation dimensions provide a layered view of product-market fit and guide prioritization of development, commercialization, and customer support investments.

How regional healthcare infrastructure, regulatory approaches, and strategic partnerships drive differentiated adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific

Regional dynamics in companion diagnostics are shaped by distinct healthcare infrastructures, regulatory approaches, and investment ecosystems. In the Americas, integrated healthcare providers, robust clinical trial networks, and a large biotechnology sector foster early adoption of novel diagnostics and close clinician-industry collaboration. This environment supports iterative validation and clinical utility studies that bridge research findings with clinical pathways, while reimbursement dialogues increasingly center on value demonstration and outcome alignment.

Europe, the Middle East & Africa display heterogeneous adoption curves influenced by diverse regulatory regimes and payer landscapes. Robust academic centers and centralized public health systems in parts of Europe facilitate multicenter collaborations and standardization efforts, whereas markets across the Middle East and Africa often emphasize capacity building, laboratory infrastructure modernization, and regional harmonization. Cross-border partnerships and diagnostic hubs play a vital role in extending advanced testing capabilities to broader patient populations in these regions.

The Asia-Pacific region is notable for rapid investment in laboratory infrastructure, growing domestic diagnostic manufacturing, and large patient cohorts that enable translational research and real-world evidence generation. Government-led initiatives to expand precision medicine programs and the presence of high-volume clinical sites create opportunities for scaling diagnostic services. Across regions, stakeholders must navigate differing regulatory timelines, reimbursement frameworks, and infrastructure constraints, tailoring market entry and partnership strategies to regional realities while leveraging global evidence generation to support broader adoption.

Insights into competitive positioning, partnerships, and capability stacks that determine success for diagnostic developers, laboratories, and integrated service providers

Competitive dynamics in companion diagnostics are shaped by a mix of specialized assay developers, instrument manufacturers, clinical laboratory networks, and integrated diagnostic-therapeutic partnerships. Companies with deep expertise in analytical chemistry, molecular biology, or pathology have leveraged proprietary platforms and validated workflows to establish clinical credibility. At the same time, firms that combine scalable manufacturing, regulatory experience, and collaborative development models have shown an ability to accelerate clinical translation and market entry for companion tests.

Strategic collaborations between diagnostic developers and pharmaceutical sponsors remain a critical pathway for co-developing tests that align tightly with therapeutic modalities. These partnerships often extend into evidence generation, coding and reimbursement strategy, and post-market surveillance. In addition, laboratory service providers that deliver end-to-end testing capabilities, including centralized and distributed service models, play a vital role in bridging innovation with clinical access. Companies that invest in robust quality systems, interoperability with electronic health records, and clinician-facing reporting tools tend to achieve stronger adoption and integration into care pathways.

Emerging competitive pressure comes from firms that combine diagnostics with advanced analytics and decision-support solutions, enabling more actionable, longitudinal interpretations of biomarker data. These hybrid offerings suggest the market is shifting toward value propositions that marry analytical performance with clinical utility and workflow efficiency, rewarding organizations that can demonstrate tangible improvements in patient management and health system outcomes.

Actionable strategic imperatives for diagnostic developers and health systems to align innovation, supply chain resilience, and collaborative evidence generation

Industry leaders should prioritize a few strategic imperatives to navigate the evolving diagnostics environment effectively. First, align product development with demonstrable clinical utility and operational feasibility by embedding end-user needs into assay design, validating performance across representative workflows, and ensuring reporting outputs integrate with clinical decision-making processes. This alignment reduces adoption friction and supports payer discussions focused on outcome improvements rather than analytic novelty.

Second, strengthen supply chain resilience by diversifying suppliers, considering regional manufacturing or assembly where feasible, and incorporating tariff and logistics scenarios into procurement planning. Proactive vendor partnerships and long-term agreements with contingency clauses can reduce exposure to trade and distribution disruptions and support reliable laboratory operations.

Third, cultivate strategic collaborations with pharmaceutical sponsors, clinical networks, and health systems to co-generate evidence and accelerate clinical integration. These collaborations should be structured to share risks and align incentives around demonstrable patient benefits. Investing in data infrastructure and analytics capabilities enables more persuasive real-world evidence generation and continuous performance monitoring.

Finally, invest in commercialization models that reflect end-user realities, including hybrid distribution approaches that combine direct institutional engagement, distributor partnerships, and digital channels for consumables. Complementing product innovation with clinician education, payer engagement plans, and streamlined regulatory strategies will increase the likelihood of successful uptake and sustained clinical use.

A transparent mixed-methods research framework combining expert interviews, regulatory document analysis, and case study synthesis to derive actionable diagnostic insights

The research approach blends qualitative and quantitative techniques to produce a comprehensive understanding of the companion diagnostics landscape. Primary inputs include interviews with clinical thought leaders, laboratory directors, regulatory experts, and commercial stakeholders to capture operational challenges, adoption drivers, and unmet clinical needs. These conversations inform a framework for evaluating analytical platforms, assay performance characteristics, and integration barriers within real-world clinical workflows.

Secondary research encompasses a broad review of peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and public policy statements to ground the analysis in current scientific and regulatory context. Comparative case studies of successful diagnostic-therapeutic co-development efforts were analyzed to extract best practices and common pitfalls in evidence generation, regulatory strategy, and market access planning.

Synthesis involved triangulating primary and secondary findings to develop scenario-based implications for supply chain design, commercialization pathways, and regional entry strategies. Validation workshops with industry stakeholders were used to refine conclusions and ensure practical relevance. This mixed-methods design emphasizes transparency in assumptions, traceability of insights to source inputs, and actionable recommendations tailored to organizational decision-making needs.

Concise conclusion synthesizing technological, regulatory, and commercial imperatives to guide strategic investments and clinical integration of companion diagnostics

In summary, companion diagnostics are increasingly central to precision medicine, reshaping clinical pathways, trial designs, and commercial models. Technological advancements in sequencing and assay multiplexing, coupled with evolving regulatory and reimbursement dialogues, are elevating the expectations for clinical utility and operational readiness. Supply chain and trade policy dynamics add complexity, making resilience and strategic sourcing essential components of commercialization planning.

Segmentation across product type, application, end user, and distribution channel highlights distinct development and go-to-market requirements, while regional dynamics require tailored strategies that reflect infrastructure, regulatory, and payer differences. Competitive advantage accrues to organizations that combine analytical excellence with robust evidence generation, strategic partnerships, and clinician-aligned reporting and workflow integration. Taken together, these insights provide a coherent foundation for leaders seeking to prioritize investments and accelerate clinical integration of companion diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiomic biomarkers into companion diagnostic assays for personalized therapies
  • 5.2. Expansion of liquid biopsy based companion diagnostics for real-time treatment monitoring
  • 5.3. Adoption of digital pathology and AI algorithms in companion diagnostic result interpretation
  • 5.4. Collaboration between pharmaceutical and diagnostic developers for co-development of targeted therapies
  • 5.5. Emergence of cost-effective point-of-care companion diagnostic platforms in emerging markets
  • 5.6. Regulatory harmonization initiatives to streamline companion diagnostic approvals across major regions
  • 5.7. Development of multiplex companion diagnostics enabling simultaneous profiling of multiple biomarkers
  • 5.8. Growing investment in next-generation sequencing panels for comprehensive companion diagnostic testing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Diagnostics Market, by Product Type

  • 8.1. Immunohistochemistry
  • 8.2. In Situ Hybridization
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Digital Pcr
    • 8.4.2. Quantitative Pcr

9. Companion Diagnostics Market, by Application

  • 9.1. Genetic Disorders
  • 9.2. Infectious Diseases
  • 9.3. Oncology
  • 9.4. Pharmacogenomics

10. Companion Diagnostics Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Pharmaceutical Companies

11. Companion Diagnostics Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distributor Sales
  • 11.3. Online Sales

12. Companion Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. QIAGEN N.V.
    • 15.3.4. Abbott Laboratories
    • 15.3.5. Illumina, Inc.
    • 15.3.6. Danaher Corporation
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. bioMerieux SA
    • 15.3.9. Agilent Technologies, Inc.
    • 15.3.10. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 272. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 273. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 274. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 275. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 314. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION